戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 st and after administration of dobutamine or esmolol.
2 obutamine and decreased with the infusion of esmolol.
3 ntly higher with sotalol than they were with esmolol.
4 icantly higher with sotalol than it was with esmolol.
5 ent manner; such an effect was not seen with esmolol.
6 tropic modulation stages with dobutamine and esmolol.
7 re was induced with a continuous infusion of esmolol.
8 ttributed to the anti-inflammatory effect of esmolol.
9 y but not that for betaxolol, bisoprolol, or esmolol.
10 e beta1-binding of betaxolol, bisoprolol, or esmolol.
11 ration of the beta-adrenoreceptor antagonist esmolol (1 mg kg(-1)) also attenuated the effect of vaga
12 .8+/-3.0 degrees ) LV twist was reduced with esmolol (11.2+/-3.3 degrees ; P=0.007) and augmented dur
13 5+/-5.4 degrees ; P=0.004), and reduced with esmolol (13.0+/-3.8 degrees ; P<0.001) and Spo(2) normal
14 zed after a run-in phase (1 week) to receive esmolol, 14%, gel with standard of care (SoC), SoC only,
15 0/min, 40% inspiratory time) under baseline, esmolol (2 mg/min), dobutamine infusions (5 microg/kg/mi
16 ld-type mice survived challenge with 4 mg/kg esmolol, 6 of 8 compound Ero1l and Ero1lb mutant mice su
17  wild-type mice (beta 1+/+ ) with or without esmolol (a selective beta 1 -adrenergic receptor blocker
18 on and that the short-acting beta-antagonist esmolol administered at reperfusion would protect agains
19 is was more pronounced after RFA than during esmolol administration (23 +/- 11 mm vs. 7 +/- 5 mm, res
20 ated animals were significantly better after esmolol administration and duration of survival was sign
21    The difference in caudal shift seen after esmolol administration and following SN modification sug
22 were obtained at baseline and 24 hours after esmolol administration.
23 normalized Spo(2) lowered twist further than esmolol alone (10.5+/-3.1 degrees ; P=0.036).
24 smolol+hypoxia augmented twist compared with esmolol alone (16.5+/-3.3 degrees ; P<0.001).
25 elastance during contractility modulation by esmolol and dobutamine and assessed during preload reduc
26 elastance during contractility modulation by esmolol and dobutamine and during preload reduction and
27 change and peak ejection rate decreased with esmolol and increased with dobutamine.
28  created a model of global LV dysfunction by esmolol and phenylephrine infusion in six dogs, initiall
29 mean time of contraction were prolonged with esmolol and shortened with dobutamine.
30 tions and after sequential administration of esmolol and sotalol.
31 nts received infusions of beta(1)-AR blocker esmolol and volume-matched saline (double-blind, randomi
32 ment: 6 left stellate ganglionic blockade, 7 esmolol, and 14 propranolol.
33 phen, as well as alpha-2 agonists, ketamine, esmolol, and nonpharmacologic approaches (e.g., transcut
34                                              Esmolol before reperfusion improved return of spontaneou
35                                              Esmolol did not improve orthostatic tolerance or hemodyn
36                                      Without esmolol, dobutamine stress induced myocardial ischemia w
37                                              Esmolol, dobutamine, and atropine were used to track var
38 le animals were treated with a beta-blocker, esmolol, during a severe hypercapnic acidosis challenge.
39 t rates were achieved in all patients in the esmolol group compared with those in the control group.
40 0.11 mug/kg/min (IQR, -0.46 to 0.02) for the esmolol group vs -0.01 mug/kg/min (IQR, -0.2 to 0.44) fo
41  hours was -28/min (IQR, -37 to -21) for the esmolol group vs -6/min (95% CI, -14 to 0) for the contr
42  Twenty-eight day mortality was 49.4% in the esmolol group vs 80.5% in the control group (adjusted ha
43       Fluid requirements were reduced in the esmolol group: median AUC was 3975 mL/24 h (IQR, 3663 to
44       Preclinical and phase 1/2 studies with esmolol hydrochloride suggest its potential role in trea
45 oxia (19.6+/-4.9 degrees ; P<0.001), whereas esmolol+hypoxia augmented twist compared with esmolol al
46                       Phenylephrine, but not esmolol, improves orthostatic tolerance and hemodynamics
47 als were randomized to receive 300 microg/kg esmolol in a volume of 200 microL or an equivalent volum
48 ephrine, and a beta-1 adrenergic antagonist, esmolol, in 14 patients with POTS aged 13 to 19 years.
49 gnitude lead was significantly reduced after esmolol infusion (P<0.001), and the number of positive T
50                                              Esmolol infusion decreased both pulse pressure variation
51 trated that heart rate control by a titrated esmolol infusion in septic shock patients was associated
52                                              Esmolol infusion increased cardiac contractility and res
53 han or equal to 65 mm Hg received a titrated esmolol infusion to maintain heart rate less than 95 bea
54                                              Esmolol infusion was also associated with an up-regulati
55 sitropic state was changed by dobutamine and esmolol infusion.
56 sitropic state was changed by dobutamine and esmolol infusion.
57 fusion up to 1 h, followed by dobutamine and esmolol infusions.
58                                              Esmolol led to a decrease in IVA and dP/dt(max).
59                                     Study 1: Esmolol led to a decrease in IVA and Emax (P<0.03 and <0
60 l experimental stages (baseline, dobutamine, esmolol) led to a significant decrease (P < or = 0.01) i
61 tile amplitude, force, and frequency whereas esmolol markedly decreased these contractile properties.
62                  With these results, topical esmolol may be an appropriate addition to SoC for treati
63                   Animals received 1.0 mg/kg esmolol (n=8) or saline (n=8) intravenously at the start
64 s measured again after sympathetic blockade (esmolol, n=20), parasympathetic blockade (atropine, n=20
65 prusside, diazoxide, hydralazine, labetalol, esmolol, nicardipine, nifedipine, enalaprilat, and minox
66  allocated to the following groups: control, esmolol, norepinephrine (started at 18 hr after the surg
67                                    Moreover, esmolol+normalized Spo(2) lowered twist further than esm
68                    Currently, the effects of esmolol on in vivo cardiac function and on vascular func
69 e the effects of the beta1-selective blocker esmolol on myocardial and vascular function in peritonit
70 Opposing significant decreases occurred with esmolol: peak systolic velocity of 4.46 +/- 0.94 to 2.31
71 n, and per-protocol population comparing the esmolol plus SoC and SoC only treatment groups.
72                                              Esmolol prevented dobutamine-induced ischemia (lactate p
73 nt relation between APD and LV (+)dP/dt with esmolol (r = 0.27, p = NS).
74 hmic agents (i.e., adenosine, verapamil, and esmolol, respectively) until the arrhythmia was terminat
75 riuretic peptide, exenatide, metoprolol, and esmolol) stand unchallenged to date in reducing infarct
76 ne (started at 18 hr after the surgery), and esmolol (started at 4 hr after the surgery) + norepineph
77 patients to receive a continuous infusion of esmolol titrated to maintain heart rate between 80/min a
78 double-blind clinical trial, the addition of esmolol to SoC was shown to significantly improve the he
79                                              Esmolol-treated animals required a significantly smaller
80                                  Each of the esmolol-treated but only five of nine placebo-treated an
81 tain heart rate between 80/min and 94/min by esmolol treatment over a 96-hour period.
82 <0.05]) and decreased with administration of esmolol (v(endo) 1.4+/-0.2 cm/s [P<0.05]; SR 6+/-1 s(-1)
83  patients in septic shock, open-label use of esmolol vs standard care was associated with reductions
84      For arterial lactatemia, median AUC for esmolol was -0.1 mmol/L (IQR, -0.6 to 0.2) vs 0.1 mmol/L
85 s the left ventricular stroke work index for esmolol was 3 mL/m2 (IQR, 0 to 8) vs 1 mL/m2 for the con
86  For stroke volume index, the median AUC for esmolol was 4 mL/m2 (IQR, -1 to 10) vs 1 mL/m2 for the c
87 ge in activation after the administration of esmolol was also assessed and compared to the shift docu
88 iest activation site after administration of esmolol was compared with the shift after RFA.
89 c abnormalities elicited with this infusion, esmolol was infused at 50 micrograms/kg body weight per
90 g beta1-selective adrenergic blocking agent, esmolol, was administrated during cardiopulmonary resusc
91  and caval occlusion, whereas dobutamine and esmolol were used to change LV and LA relaxation.
92 mine infusion than with that performed after esmolol with atropine added at the maximal dobutamine do
93 re within the 12-week treatment phase in the esmolol with SoC and SoC only groups.
94 eved in 44 of 57 (77.2%) participants in the esmolol with SoC group and 35 of 63 (55.6%) participants
95 n time for ulcer closure was 85 days for the esmolol with SoC group and was not estimable for SoC onl
96        The proportion of participants in the esmolol with SoC group who achieved target ulcer closure
97                      Significant benefits of Esmolol with SoC were seen in patients with factors that
98 shock using the beta-1 adrenoceptor blocker, esmolol, with specific focus on systemic hemodynamics an